Starting antipsychotics for early psychosis: an imaging study
Part of Hormones & metabolism, Mental health clinical trials.
This study looks at people with early psychosis who are about to start a new antipsychotic medication. It uses brain scans to understand how these medications work. If you are starting a new antipsychotic or changing your dose, this trial may be for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a patient at the PEP clinic in Estrie (Quebec) for early psychosis.
- You are willing to start a new antipsychotic or change your dose.
- You can read and speak in English or French.
- You have not taken any antipsychotic for more than 2 weeks in the past year, except very low doses of aripiprazole or quetiapine.
- You do not have certain conditions like borderline personality disorder, autism, or substance-induced psychosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special drink with ketones can help people recover faster while taking antipsychotic medication for early psychosis. It may be a safe way to boost brain energy and reduce side effects.
This study uses brain scans to find markers that can predict how well antipsychotic medications work in people having their first episode of psychosis. It aims to help doctors choose the right treatment earlier.
This study looks at whether special body and brain markers can predict how a person’s symptoms change over two years after a first psychotic episode. It may also help doctors understand who responds better to treatment, so future care can be more personalized.
This trial looks at people having a first psychotic episode who have not yet taken anti-psychotic medicine. It aims to see whether an early support approach can help, before other treatments become necessary.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This study examines the brain in people having their first episode of psychosis (like hearing voices or strong false beliefs) to understand more about schizophrenia and related conditions. It involves MRI scans and other tests over one year.
Hear when a new Metabolic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.